VistaGen Therapeutics
Stock Forecast, Prediction & Price Target
VistaGen Therapeutics Financial Estimates
VistaGen Therapeutics Revenue Estimates
VistaGen Therapeutics EBITDA Estimates
VistaGen Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2026 | 3/31/2027 | 3/31/2028 | 3/31/2029 |
Revenue
% change YoY
| $1.10M N/A | $-227K -120.47% | $1.06M 568.72% | Avg: $263.67K Low: $211.73K High: $315.60K avg. -75.21% | Avg: $2.5M Low: $2.00M High: $2.99M avg. 848.15% | Avg: $69.85M Low: $56.09M High: $83.60M avg. 2694.04% | Avg: $260.37M Low: $209.08M High: $311.66M avg. 272.75% |
Net Income
% change YoY
| $-47.76M N/A | $-59.24M -24.04% | $-29.36M 50.44% | Avg: $-82.07M Low: $-56.90M High: $-24.58M avg. -179.51% | Avg: $-78.48M Low: $-41.80M High: $-29.61M avg. 4.37% | Avg: $-17.99M Low: $-22.60M High: $-13.39M avg. 77.06% | Avg: $23.80M Low: $17.71M High: $29.90M avg. 232.25% |
EBITDA
% change YoY
| $-46.81M N/A | $-58.73M -25.46% | $-32.45M 44.74% | Avg: $-52.73K Low: $-63.12K High: $-42.34K avg. 99.83% | Avg: $-499.99K Low: $-598.48K High: $-401.51K avg. -848.17% | Avg: $-13.97M Low: $-16.72M High: $-11.21M avg. -2694.04% | Avg: $-52.07M Low: $-62.33M High: $-41.81M avg. -272.75% |
EPS
% change YoY
| -$7.24 N/A | -$8.51 -17.54% | -$1.52 82.13% | Avg: -$1.89 Low: -$2.94 High: -$1.27 avg. -24.12% | Avg: -$1.85 Low: -$2.16 High: -$1.53 avg. 2.20% | Avg: -$0.93 Low: -$1.17 High: -$0.69 avg. 49.59% | Avg: $1.23 Low: $0.92 High: $1.54 avg. 232.25% |
Operating Expenses
% change YoY
| $48.65M N/A | $59.04M 21.34% | $34.08M -42.26% | Avg: $-1.59M Low: $-1.90M High: $-1.27M avg. -104.67% | Avg: $-15.10M Low: $-18.07M High: $-12.12M avg. -848.15% | Avg: $-421.95M Low: $-505.07M High: $-338.84M avg. -2694.04% | Avg: $-1.57B Low: $-1.88B High: $-1.26B avg. -272.75% |
FAQ
What is VistaGen Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 33.54% in 2026-2029.
We have gathered data from 2 analysts. Their low estimate is -56.90M, average is -82.07M and high is -24.58M.
What is VistaGen Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 934.93% in 2026-2029.
We have gathered data from 2 analysts. Their low revenue estimate is $211.73K, average is $263.67K and high is $315.60K.
What is VistaGen Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 64.98% in 2026-2029.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$2.94, average is -$1.89 and high is $-1.27.
What is the best performing analyst?
In the last twelve months analysts have been covering VistaGen Therapeutics stock. The most successful analyst is Andrew Tsai whose win rate is 100%. He has correctly predicted 1/1 price targets.